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Abstract
!
Recent evidence suggests that cardiac glycosides
might be used for the treatment of cancer. The or-
namental shrub Nerium oleander has been used in
traditional medicine for treating several disorders
including cancer, and extracts from the leaves of
this plant have already entered phase I clinical tri-
als. In this communication, we have prepared a
hydroalcoholic extract from the leaves of Nerium
oleander (containing 4.75 ± 0.32% of cardenolides)
and have assessed its cytotoxic activity in A549
lung cancer cells vs. MRC5 nonmalignant lung fi-
broblasts. The results showed that the cytotoxic-
ity of the Nerium oleander extract against the can-
cer cell line was significantly higher than that
against the nonmalignant cell line, with a potency
and selectivity similar to those of the anticancer
drug cisplatin. Pretreatment of A549 cells with
the antioxidants N-acetylcysteine and catalase
slightly prevented the cytotoxicity of the extract,
therefore suggesting that the formation of reac-
tive oxygen species participates in its cytotoxic
activity but does not play a major role. Nerium
oleander extract-induced cytotoxicity and DNA
damage (gamma-H2AX focus formation) were
slightly higher in cells lacking BRCA2 (deficient
in homologous recombination repair) than in par-
ental cells; this indicates that the induction of
DNA damagemay also play a role in the cytotoxic-
ity of the extract. Nerium oleander extract in-
duced a marked inhibition of glycolysis (glucose
consumption and lactate production) in A549
cells, comparable to that of the glycolysis inhibitor
dichloroacetate (currently in clinical develop-
ment for cancer therapy). Because platinum com-
pounds are widely used in the treatment of lung
cancer, we tested the cytotoxicity of several com-
binations of cisplatin with the extract and found a
moderate synergism when Nerium oleander ex-
tract was administered after cisplatin but a mod-
erate antagonism when it was added before cis-
platin. Our results suggest that extracts from Ne-
rium oleander might induce anticancer effects in
patients with lung cancer and support their possi-
ble advancement into phase II clinical trials for
the treatment of this type of cancer.
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l.Introduction
!
Cardiac glycosides are a group of natural products
that share a steroid-like structure with an un-
saturated lactone ring and the ability to inhibit
the Na+/K+-ATPase pump. The lactone moiety at
position 17 defines the two classes of cardiac gly-
coside: cardenolides (with the lactone 2-fu-Calderón-Montaño JM et al.ranone) and bufadienolides (with the lactone 2-
pyrone). Numerous cardiac glycosides (e.g., digi-
toxin, digoxin, ouabain, oleandrin, and proscillar-
idin) have been isolated from plants (e.g., Digitalis
purpurea, Digitalis lannata, Strophantus gratus,
Nerium oleander, and Urginea martima). Several
cardiac glycosides have also been found in am-
phibians and mammals, including digoxin, oua-A Hydroalcoholic Extract… Planta Med 2013; 79: 1017–1023
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l.bain, bufalin, marinobufagenin, and telecinobufagin. Some car-
diac glycosides are used in cardiology for the treatment of cardiac
congestion and some types of cardiac arrhythmias. The mecha-
nism by which these drugs affect cardiac contractility is known
to be mediated by a highly specific inhibition of Na+/K+-ATPase
[1–3].
Over the years, there have been a variety of periodic reports sug-
gesting that cardiac glycosides may have an anticancer utilization
(reviewed in [4–8]). In vitro and ex vivo experiments have re-
vealed that some cardiac glycosides (e.g., digitoxin) induce selec-
tive anticancer effects [4,9,10], which may occur at concentra-
tions commonly found in the plasma of patients treated with
these drugs [11]. Some cardiac glycosides have also shown potent
and selective anticancer effects in mice harboring human malig-
nant cells [12,13]; however, these results should be interpreted
cautiously, as mouse cells are much more resistant than human
cells to the cytotoxic effects of cardiac glycosides, and it is not
clear whether such selectivity is due to selective inhibition of tu-
mor cells or to interspecies differences in sensitivity [14]. The
cardiac drugs digitoxin and digoxin, the semisynthetic cardiac
glycoside UNBS1450, and two extracts from Nerium oleander
Apocynaceae have entered clinical trials for the treatment of can-
cer (see http://clinicaltrials.gov/ and ref. [6,7,15,16]). Recently,
however, Perne et al. reported results suggesting that cardiac gly-
coside-induced cytotoxicity was mediated by general protein
synthesis inhibition and was not selective for cancer cells, raising
concerns about ongoing clinical trials testing cardiac glycosides
as anticancer agents [17]. Later, Hallbook et al. observed that
some cardiac glycosides, particularly digitoxin, induced ex vivo
selective anticancer effects in leukemia cells and found that pro-
tein synthesis inhibition by cardiac glycosides at concentrations
corresponding to IC50 values did not occur in all types of cancer
cells [10]. These data suggest that cardiac glycosides may induce
selective anticancer effects only in some types of cancer.
Several mechanisms of action have been proposed to participate
in the cytotoxic activity of cardiac glycosides (reviewed in [5–8,
16]). However, it is unclear why cancer cells are generally more
susceptible than nonmalignant cells to the cytotoxic activity of
these compounds. Recent data have revealed that cancer cells
have a higher reliance on glycolysis for their survival than normal
cells, and that the inhibition of glycolysis may cause selective
anticancer effects [5,18,19]. In this communication, we have as-
sessed the selective cytotoxic activity of a hydroalcoholic extract
from the leaves of the cardenolide-containing plant Nerium ole-
ander against A549 lung cancer cells vs. MRC5 nonmalignant lung
fibroblasts and have evaluated possible mechanisms involved in
this activity. Results show that this extract induces selective kill-
ing of lung cancer cells and a marked inhibition of glycolysis.Materials and Methods
!
Plant material, preparation of the extract,
and determination of cardiac glycosides content
The leaves of Nerium oleander L. were collected in June 2010 in
Seville (Spain; 37°22′16′′N, 5°59′ 27′′W). A voucher specimen
(278048) was authenticated by Dr. F. Garcia and is deposited in
the herbarium at the Department of Vegetal Biology and Ecology,
Faculty of Biology, University of Seville. Fresh leaves of
N. oleander were extracted with ethanol :water (1 :1) at 60°C for
1 hour by using an ultrasound water bath apparatus. Ethanol was
eliminated in a rotary vacuum evaporator, and the remainingCalderón-Montaño JM et al. A Hydroalcoholic Extract… Planta Med 2013; 79: 1017water solution was lyophilized, with an extraction yield of 2.3%.
The cardiac glycoside content ofN. oleanderwas determinedwith
the Kedde reaction, a colorimetric technique that allows the de-
termination of unsaturated pentacyclic lactones (present in car-
diac glycosides fromN. oleander) by using 3,5-dinitrobenzoic acid
[20]. Briefly, a 3% solution of 3,5-dinitrobenzoic acid in ethanol
was mixed in the ratio 1:1 with a solution of 2M NaOH in dis-
tilled water. 100 µL of this mixture was mixed with 150 µL of
NOE or 2-furanone in ethanol at different concentrations. Optical
densities were measured at 540 nm on a multiwell plate spectro-
photometer reader. Based on the standard 2-furanone (lactone of
cardenolides), the percentage of cardenolides in the extract was
determined, and was expressed as the mean ± SEM.
Chemicals and cell lines
Cisplatin (99.9%), dichloroacetate (98%), NAC (99%), 2-furanone
(97%), and catalase were purchased from Sigma. The human
A549 lung cancer cell line, the human embryo lung fibroblastic
MRC-5 cell line and the human HT29 colon adenocarcinoma cell
line were purchased from European Collection of Cell Cultures.
The human UACC-62 melanoma cell line was purchased from
American Type Culture Collection. The HR-deficient VC8 cell line
(V79 Chinese hamster lung cells mutated in BRCA2) and the
VC8B2 cell line (VC8 cells complemented with human BRCA2)
were kindly provided by Dr. Helleday. All cell lines were main-
tained in DMEM supplemented with 2mM glutamine, 50 µg/mL
penicillin, 50 µg/mL streptomycin, and 10% fetal bovine serum,
and were cultured at 37°C in a humidified atmosphere contain-
ing 5% CO2. Cell culture reagents were obtained from Life Tech-
nologies.
Assay for cytotoxic activity
The MTT assay is a colorimetric technique that allows the quanti-
tative determination of cell viability. It is based on the capability
of viable cells to transform the MTT salt (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) into a formazan dye. Ex-
ponentially growing cells were seeded into 96-well plates and
drugs were added 24 h later. Following the incubation period
specified in the figures and table legends, the medium was re-
moved, and 125 µL MTT (1mg/mL in medium) was added to each
well for 4 hours. Then, 80 µL 20% SDS in 0.02M HCl were added,
plates were incubated for 10 hours at 37°C, and optical densities
were measured at 540 nm on a multiwell plate spectrophotome-
ter reader. Cell viability was expressed as percentage in relation
to controls. All data were averaged from at least three indepen-
dent experiments and were expressed as means ± SEM.
Immunofluorescence γ-H2AX focus assay
The immunofluorescence γ-H2AX focus assay is a sensitive tech-
nique to evaluate DNA damage. It is based on the ability of DSBs
to trigger phosphorylation of histone H2AX on Ser-139, which
leads to the formation of nuclear foci that can be visualized with
anti-γH2AX antibodies [21,22]. Cells were seeded on coverslips
and allowed to attach for 24 hours. After treatments, cells were
washed three times with PBS, fixed with 4% paraformaldehyde
in PBS for 10min at room temperature and washed again three
times with PBS. After fixation, cells were permeabilized with
0.5% Triton X-100 in PBS for 5 minutes and then blocked three
timeswith 0.1% Tween 20, 1% BSA in PBS for 5minutes each. Cells
were then incubated for 30minwith amouse anti-γH2AXmono-
clonal antibody (Upstate, 1 :1000 dilution). Cells were washed
three timeswith PBS and blocked three times prior to the incuba-–1023
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l.tion with a secondary anti-mouse antibody linked to Alexa Fluor
488 (Invitrogen, 1 :1000 dilution) for 1 h. Cells were washedwith
PBS, blocked andwashed againwith PBS as indicated before. DNA
was stained with DAPI, and immunofluorescence was observed
at 40-fold magnification with an Olympus BX 61 microscope. A
total of ~ 200 cells/dose were scored, and cells with 20 or more
foci were scored as positive. Ionizing radiation was used as a pos-
itive control for the assay; cells were exposed to 4 Gy of ionizing
radiation using an X‑ray irradiator (Philips MU15F) operated at
100 KV and a dose rate of 1 Gy/min [23].
Inhibition of glycolysis
Glycolysis inhibition was assessed by measuring concentrations
of glucose (initial product of glycolysis) and lactate (final product
of glycolysis) in control and treated cells. Briefly, 106 cells were
exposed in 6-well plates to the tested compounds for 8 h, and glu-
cose and lactate concentrations were determined in cell superna-
tants by using the Accutrend® Plus analyzer together with Accu-
trend glucose strips and BM-Lactate Strips (Roche Diagnostics).
After calibrating the instrument with glucose and lactate calibra-
tion strips, test strips were used to determine glucose and lactate
levels via colorimetric-oxidase mediator reactions according to
the manufacturerʼs instructions [24]. Results are expressed as
percentage of lactate production and percentage of glucose con-
sumption in relation to untreated cells and are shown as means ±
SEM of three independent experiments.
Statistical analysis
All data were averaged from at least three independent experi-
ments and were expressed as means ± SEM. For statistical analy-
sis we used the t-test (paired, two-tailed). A p value > 0.05 is not
considered statistically significant and is not represented by any
symbol. A p value < 0.05 is considered to correspond with statis-
tical significance and is indicated with an asterisk (*), a p value
< 0.01 is indicated with a double asterisk (**), and a p value
< 0.001 is indicated with a triple asterisk (***).D
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Extracts from the leaves of the cardiac glycoside-containing plant
Nerium oleander L. have shown anticancer effects in preclinical
studies andhave entered phase I clinical trials [16,25,26]. Because
recent data suggest that cardiac glycosides may induce selective
anticancer effects only in some types of cancer cells [10,17], the
aim of this work was to evaluate whether an extract from this
plant induced selective cytotoxic activity in lung cancer cells and
toevaluatepossiblemechanisms involved in this activity. Ahydro-
alcoholic extract from the leaves of N. oleanderwas prepared, and
its content in cardiac glycosides (cardenolides)was determined to
be 4.75 ± 0.32% with the Kedde reaction, which is an accepted
methodology for standardizing cardenolides. Another reason for
selecting the Kedde reaction for standardizing the extract is that,
unlike a chromatographic profile of several of its major constitu-
ents, this reaction gives its total cardenolide content. Several ex-
tracts fromN. oleander (but not anyof their constituents) have en-
tered clinical trials, therefore suggesting that their anticancer ac-
tivity ismediated by their total cardenolide content rather thanby
any particular constituent of the extracts. In addition, it is much
easier for any researcher wanting to reproduce our results to use
the Kedde reaction than to carry out a chromatographic profile of
several constituents of the extract selected by us.Calderón-A549 lung cancer cells and MRC5 nonmalignant lung fibroblasts
were exposed for 48 h to several concentrations of this NOE
under the same experimental conditions, and cell viability was
estimated with the MTT assay. Results, represented in l" Fig. 1,
show that NOE exhibited selective cytotoxicity against the A549
cancer cell line, which was comparable to that of the anticancer
drug cisplatin. The IC50 value (means ± SEM) in this cancer cell
line was approximately 10-fold lower for NOE (0.27 ± 0.04 µg/
mL) than for cisplatin (3.51 µg/mL; 11.67 ± 3.54 µM). Several com-
pounds were screened against these two cell lines and showed no
selective cytotoxicity [27,28]. We have also prepared and as-
sessed the cytotoxic activity of an extract of commercial broccoli
under the same experimental conditions used for NOE, and we
did not observe selective cytotoxicity against the cancer cell line
(data not shown). We also evaluated the cytotoxic activity of NOE
in the human HT29 colon cancer cell line and in the human
UACC62 melanoma cell line and observed that these cancer cells
were more resistant than A549 lung cancer cells to the cytotoxic-
ity of NOE; the IC50 values (means ± SEM) were 3.95 ± 0.37 µg/mL
in HT29 cells and 1.73 ± 0.07 µg/mL in UACC62 cells. Although
NOE inhibited the growth of the cancer cell lines HT29 and
UACC62 at low concentrations, these concentrations also inhib-
ited the growth of the nonmalignant cell line MRC5 (l" Fig. 1B).
Overall, these data indicate that NOE inhibits the growth of
A549 cancer cells potently and selectively.
Our next goal was to evaluate possible mechanisms involved in
the selective cytotoxicity of NOE. We initially evaluated whether
the formation of ROS played a role in the cytotoxicity of the ex-
tract. Accumulating data suggest that cancer cells have higher ba-
sal levels of ROS than nonmalignant cells, and that the induction
of a specific increase in ROS levels by pro-oxidant agents may
lead to cytotoxic concentrations in cancer cells but not in normal
cells. Indeed, oxidative stress has been shown to play an impor-
tant role in the anticancer activity of several chemotherapeutic
agents commonly used in cancer treatment [29–31] and in the
cytotoxicity of many natural products [32], including that of the
major constituent of N. oleander, oleandrin [33]. A549 cells were
treatedwith NOE in the presence and absence of the antioxidants
catalase and N-acetylcysteine, and cell viability was estimated
with the MTT assay. Both antioxidants slightly but significantly
prevented the cytotoxic activity of NOE (l" Fig. 2), therefore sug-
gesting that ROS formation participates in the cytotoxicity of NOE
but does not play a major role.
DNA-damaging compounds may induce selective cytotoxicity to-
wards tumor cells. These cells commonly have mutations in DNA
repair genes which make them vulnerable to the cytotoxic activ-
ity of specific DNA-damaging compounds. Unlike tumor cells,
normal proliferating cells have an intact DNA damage response
that would allow them to repair the DNA damage and therefore
to survive treatment with these DNA-damaging compounds [34–
36]. Because previous reports showed that some cardiac glyco-
sides induce DNA damage [11,37–39], we tested whether NOE
induced DNA damage and if such damage participated in the cy-
totoxicity of the extract. We initially tested the cytotoxicity of
NOE in cells with and without BRCA2 (a tumor suppressor gene
which plays a critical role in DNA damage repair via the HR repair
pathway). The HR-deficient VC8 cell line (V79 Chinese hamster
lung cells mutated in BRCA2) and the VC8B2 cell line (VC8 cells
complemented with human BRCA2) were exposed for 48 h to
several concentrations of NOE, and cell viability was then esti-
mated with the MTT assay. Results, represented in l" Fig. 3A,
show that the cytotoxic activity of NOE in cells lacking BRCA2Montaño JM et al. A Hydroalcoholic Extract… Planta Med 2013; 79: 1017–1023
Fig. 2 Catalase and N-acetylcisteine (NAC) slightly prevent the cytotoxic
activity of NOE. A549 cells were exposed to NOE for 48 h in the absence or
presence of the antioxidants catalase (A) and NAC (B). The antioxidants
were added 0.5 h before NOE. Cell viability was assessed by the MTT assay.
Fig. 1 A549 human
lung cancer cells are
more sensitive than
MRC5 human nonma-
lignant lung fibroblasts
to the cytotoxic activity
of Nerium oleander ex-
tract (NOE). A Repre-
sentative photographs
of A549 and MRC5 cells
cultured in 96-well
plates for 48 h in the
absence (control) or
presence of NOE (1 µg/
mL) and cisplatin
(10 µg/mL). In B and C,
the percentage of cell
viability (means ± SEM)
in A549 and MRC5 cells
exposed for 48 h to
NOE (B) and the anti-
cancer drug cisplatin
(C) was determined
with the MTT assay.
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l.(deficient in HR repair) was slightly but significantly higher than
that in parental cells, therefore suggesting that NOE can induce
DNA damage and that NOE-induced DNA damage may play a role
in its cytotoxicity. It is important to note that the cytotoxicity of
NOE in these rodent cells was over 100-fold lower than that in
human cells (l" Fig. 1), which is highly specific for cardiac glyco-
sides [40]. We next used the immunofluorescence γ-H2AX focus
assay to directly measure the levels of DNA damage induced by
NOE in both cell lines and detected moderate levels of DNA dam-
age in cells exposed for 24 h to NOE 320 µg/mL (l" Fig. 3B). As ex-
pected, the levels of DNA damage in cells lacking BRCA2 (defi-
cient in HR repair) were somewhat higher than those in parental
cells. Taken as a whole, these data suggest that NOE induces DNA
damage and that this DNA damage participates in its cytotoxic
activity but does not play a major role.
It has been known for some time that glycolysis is coupled to so-
dium and potassium transport processes and that some cardiac
glycosides (e.g., ouabain) can inhibit glycolysis in a variety of non-
malignant cells [41,42]. It has recently been found that cancer
cells are more reliant on glycolysis for their survival than non-
malignant cells (reviewed in [18,31]). Based on these findings,
we previously proposed that cardiac glycosides might inhibit gly-
colysis in cancer cells and that such inhibition might play a
critical role in the selective cytotoxicity of some cardiac glyco-Calderón-Montaño JM et al. A Hydroalcoholic Extract… Planta Med 2013; 79: 1017sides (e.g., digitoxin) towards cancer cells [5]. To test if NOE could
inhibit glycolysis, A549 cells were exposed to NOE for 8 h, and
glucose and lactate concentrations were determined in cell
supernatants. Results, represented in l" Fig. 4, show that A549
cells exposed to NOE (1 and 10 µg/mL) exhibited a marked reduc-
tion in glucose consumption and lactate production, comparable
to those observed in cells exposed to the glycolysis inhibitor DCA
32mM. No significant changes in glucose consumption and lac-
tate production were observed in cells exposed to cisplatin
32 µM. l" Fig. 4C includes representative photographs of cells ex-
posed for 8 h to NOE, DCA, and cisplatin, where cell number and
morphology can be appreciated. This figure seeks to show that
the reduction in glucose consumption and lactate production in-
duced by NOE is not caused by a reduction in cell number (fewer
cells would consume less glucose and would produce less lac-
tate). Knowing that glucose and lactate are, respectively, the ini-
tial and final products of glycolysis, our data indicate that NOE in-
duces a marked inhibition of glycolysis in A549 lung cancer cells.
As mentioned before, cardiac glycosides are known to inhibit the
Na+/K+-ATPase pump. Several mechanisms have been proposed
to explain how the inhibition of this pump can lead to glycolysis
inhibition [5]. Briefly, inhibition of the Na+/K+-ATPase pump–1023
Fig. 3 Induction of DNA damage by NOE and role of homologous recom-
bination (HR) in the repair of NOE-induced DNA damage. (A) VC8 cells
(mutated in BRCA2; deficient in HR repair) and VC8-B2 cells (VC8 cells
complemented with BRCA2; HR proficient) were exposed to several con-
centrations of NOE for 48 h, and the percentage of cell viability (means ±
SEM) was determined with the MTT assay. Representative photographs (B)
and quantification of nuclear foci (C) in VC8 and VC8-B2 cells exposed for
4 h and 24 h to NOE 320 µg/mL.
Fig. 4 NOE induces a marked inhibition of glycolysis in A549 cells. (A)
Percentage of lactate production and (B) percentage of glucose consump-
tion in A549 cells exposed for 8 h to NOE, dichloroacetate (DCA), and cis-
platin in relation to untreated cells. (C) Representative photographs of
A549 cells exposed for 8 h to NOE, dichloroacetate, and cisplatin.
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l.would decrease glycolysis activity by inhibition of the key glyco-
lytic enzyme phosphofructokinase (discussed in reference [5]). In
addition, inhibition of the Na+/K+-ATPase pump may restrict the
activity of SGLTs, which couple glucose entry into some types ofCalderón-cells with the activity of this pump [5]. Although they are typi-
cally found in small intestine and renal epithelial cells, clinical da-
ta have revealed that these transporters (SGLT2) are overex-
pressed in lung cancer cells that have metastasized to other or-
gans [43]. This suggests that SGLT2 plays a role in glucose uptake
in the metastatic lesions of lung cancer, and that inhibition of the
Na+/K+-ATPase pump by cardiac glycosides may inhibit glycolysis
by reducing glucose entry into the cells. The inhibition of glycol-
ysis induced by NOE in A549 lung cancer cells may therefore be
caused by inhibition of the Na+/K+-ATPase pump, which would
lead to both the inhibition of the glycolytic enzyme PFK and the
inhibition of glucose entry into the cells.
Glycolysis inhibition is well known to produce cytotoxicity. The
main cellular roles of glycolysis are to provide building blocks
for biosynthesis and ATP, and evidence suggests that inhibition
of these processes may have a higher impact on the viability of
cancer cells than on that of nonmalignant cells. Indeed, glycolysis
inhibition has been proposed to be an anticancer strategy to se-
lectively kill cancer cells [18,31]. Although here we report that
NOE induces selective cytotoxicity against lung cancer cells andMontaño JM et al. A Hydroalcoholic Extract… Planta Med 2013; 79: 1017–1023
Table 1 Cytotoxic activity of NOE in combination with the anticancer drug cisplatin.
First compound added Second compound added Combination
Concentration % Cell viability Concentration % Cell viability % Cell viability CI Effect
1 µM cisplatin 85.97 ± 1.63 32 ng/mL NOE 81.30 ± 2.07 80.11 ± 2.44 1.40 ––
100 ng/mL NOE 65.57 ± 0.24 58.73 ± 0.44 1.08 ±
320 ng/mL NOE 28.50 ± 4.01 24.69 ± 1.52 0.76 ++
3 µM cisplatin 72.59 ± 2.81 32 ng/mL NOE 81.30 ± 2.07 64.79 ± 5.82 0.97 ±
100 ng/mL NOE 65.57 ± 0.24 50.85 ± 0.35 0.96 ±
320 ng/mL NOE 28.50 ± 4.01 22.56 ± 1.61 0.71 ++
10 µM cisplatin 53.82 ± 0.20 32 ng/mL NOE 81.30 ± 2.07 49.81 ± 0.32 1.04 ±
100 ng/mL NOE 65.57 ± 0.24 37.15 ± 1.48 0.81 ++
320 ng/mL NOE 28.50 ± 4.01 21.24 ± 0.89 0.75 ++
32 µM cisplatin 33.00 ± 2.56 32 ng/mL NOE 81.30 ± 2.07 31.23 ± 2.21 0.99 ±
100 ng/mL NOE 65.57 ± 0.24 24.20 ± 2.84 0.77 ++
320 ng/mL NOE 28.50 ± 4.01 13.82 ± 0.52 0.58 +++
32 ng/mL NOE 90.15 ± 2.17 1 µM cisplatin 85.97 ± 1.63 84.91 ± 3.92 1.20 –
100 ng/mL NOE 72.90 ± 5.12 64.32 ± 4.00 1.00 ±
320 ng/mL NOE 24.62 ± 5.31 29.10 ± 3.90 1.09 ±
32 ng/mL NOE 90.15 ± 2.17 3 µM cisplatin 84.65 ± 3.83 75.65 ± 1.31 1.18 –
100 ng/mL NOE 72.90 ± 5.12 63.03 ± 1.93 1.17 –
320 ng/mL NOE 24.62 ± 5.31 34.03 ± 3.62 1.31 ––
32 ng/mL NOE 90.15 ± 2.17 10 µM cisplatin 59.78 ± 2.40 59.33 ± 3.62 1.09 ±
100 ng/mL NOE 72.90 ± 5.12 52.39 ± 3.55 1.19 –
320 ng/mL NOE 24.62 ± 5.31 28.95 ± 0.12 1.20 –
32 ng/mL NOE 90.15 ± 2.17 32 µM cisplatin 40.67 ± 1.93 39.37 ± 0.93 0.98 ±
100 ng/mL NOE 72.90 ± 5.12 36.72 ± 0.55 1.09 ±
320 ng/mL NOE 24.62 ± 5.31 28.45 ± 0.90 1.47 –––
A549 cancer cells were exposed for 44–48 h to several concentrations of NOE, cisplatin, and NOE in combination with cisplatin (NOE was added 4 h before cisplatin or vice versa).
Cell viability was assessed by the MTT assay. The parameter combination index (CI) was calculated with the computer software Compusyn. A CI value < 0.9 is considered to be
synergism and is represented by “+++++” for very strong synergism (CI < 0.1), “++++” for strong synergism (CI = 0.1–0.3), “+++” for synergism (CI = 0.3–0.7), “++” for moderate
synergism (CI = 0.7–0.85), and “+” for slight synergism (CI = 0.85–0.9). A CI value between 0.9 and 1.1 corresponds with the additive effect and is indicated with “±”. A CI value
> 1.1 is considered to be antagonism and is represented by “–” for slight antagonism (CI = 1.1–1.2), “––” for moderate antagonism (CI = 1.2–1.45), “–––” for antagonism
(CI = 1.45–3.3), “––– –” for strong antagonism (CI = 3.3–10), and “–––––” for very strong antagonism (CI > 10)
1022 Original Papers
D
ow
nl
oa
de
d 
by
: I
P-
Pr
ox
y 
Un
ive
rs
id
ad
 d
e 
Se
vil
la
, U
ni
ve
rs
id
ad
 d
e 
Se
vil
la
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.that this extract induces a marked inhibition of glycolysis, we
cannot conclude that NOE-induced inhibition of glycolysis is re-
sponsible for its selective anticancer activity. Evidence suggests
that the expression and cellular location of Na+/K+-ATPase alpha
subunits in different types of cells (i.e., rodent cells, human can-
cer cells, and human nonmalignant cells) may explainwhy differ-
ent cells are more or less susceptible to the cytotoxic activity of
cardiac glycosides [44–46]. The study of the possible association
between the expression and cellular location of Na+/K+-ATPase
alpha subunits and the ability of cardiac glycosides to inhibit gly-
colysis would help reveal whether the inhibition of glycolysis by
these compounds plays a role in their selective cytotoxicity.
Sincemost cancer chemotherapy regimens include a combination
of drugs, and since platinum compounds are widely used in the
treatment of lung cancer, we assessed the cytotoxic activity of
NOE in combination with cisplatin in A549 lung cancer cells.
Then, we calculated the parameter CI with the computer software
Compusyn; this parameter is based on the Chou-Talalay method
and offers a quantitative definition for the additive effect (CI = 1),
synergism (CI < 1), and antagonism (CI > 1) in drug combinations
[47]. A549 cells were exposed for 44–48 h to several concentra-
tions of cisplatin, NOE, and cisplatin in combination with NOE.
Cell viability was then estimated with theMTT assay. Results, col-
lected in l" Table 1, revealed a moderate antagonism when NOE
was added 4 h before cisplatin but a moderate synergism when
NOE was administered 4 h after cisplatin. Evidence suggests that
the Na+/K+-ATPase alpha1 subunit plays a role in the intracellular
accumulation of cisplatin and that cardiac glycosides can reduce
its intracellular accumulation [48]; thismay explain themoderateCalderón-Montaño JM et al. A Hydroalcoholic Extract… Planta Med 2013; 79: 1017antagonisms observed when cells were treated with NOE before
cisplatin (l" Table 1). Administration of NOE after cisplatin might
induce a moderate synergism by circumventing a variety of resis-
tance pathways discussed elsewhere [16,49].
In conclusion, this work reports that an extract from the leaves of
the cardiac glycoside-containing plant Nerium oleander exerts se-
lective cytotoxic activity towards lung cancer cells and induces a
marked inhibition of glycolysis that may play a role in this activ-
ity. It also shows that NOE-induced DNA damage and ROS forma-
tion participate moderately in its cytotoxicity, and that the ad-
ministration of NOE after the anticancer drug cisplatin may in-
duce synergistic cytotoxicity. Since phase I clinical trials have re-
vealed that extracts from the leaves of Nerium oleander are well
tolerated and may induce anticancer effects [16,25,26], the
present results support their possible advancement into phase II
clinical trials for the treatment of lung cancer.Conflict of Interest
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